Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05374317 · ClinicalTrials.gov registry record · Phase 4

Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine

A Phase 4 study of Yellow Fever Vaccination Reaction, sponsored by US Army Medical Research Institute of Infectious Diseases.

Completed
Registry status
Phase 4
Development phase
88
Enrollment target
1
Study location

NCT05374317 is a Phase 4 study of Yellow Fever Vaccination Reaction that has completed, run by US Army Medical Research Institute of Infectious Diseases. The registered enrollment target is 88 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05374317, a Phase 4 study of Yellow Fever Vaccination Reaction, has completed, sponsored by US Army Medical Research Institute of Infectious Diseases.

COMPLETED
Registry status
Phase 4
Development phase
88 participants
Enrollment target
1
Study location

Study Summary

This is an open-label, randomized, exploratory study to evaluate the human immune response to reduced subcutaneous (SQ) dosing of Yellow Fever vaccine compared to the standard FDA approved subcutaneous vaccination dose. The current dose of the US FDA licensed Yellow Fever vaccine is approximately 55,000 plaque-forming unit(s) (PFU) in 0.5 mL administered SQ. Using the licensed dosage as standard, investigators are evaluating reduced doses of 1/5th (0.10 mL) and 1/10th (0.05 mL) Yellow Fever vaccine (YF-VAX).

Interventions

  • BIOLOGICAL Yellow Fever Vaccine

Study Locations (1)

Maryland

  • United States Army Medical Research Institute of Infectious Diseases - Frederick

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2021-06-07
Est. Completion 2022-11-02
Phase Phase 4

What the Registry Record Tells You About NCT05374317

The ClinicalTrials.gov registry entry for NCT05374317 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Army Medical Research Institute of Infectious Diseases, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Yellow Fever Vaccination Reaction appearing as the primary indexed condition, and to 1 intervention - of which Yellow Fever Vaccine is the first listed.

NCT05374317 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT05374317 about?

NCT05374317 is a clinical study titled "Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine". This is an open-label, randomized, exploratory study to evaluate the human immune response to reduced subcutaneous (SQ) dosing of Yellow Fever vaccine compared to the standard FDA approved subcutaneous vaccination dose. The current dose of the US FDA licensed Yellow Fever vaccine is approximately 55...

What is the current status of trial NCT05374317?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 88 participants. The study started on 2021-06-07. Estimated completion is 2022-11-02.

What conditions does trial NCT05374317 study?

This clinical trial studies the following conditions: Yellow Fever Vaccination Reaction.

What interventions are being tested in trial NCT05374317?

The interventions under investigation include: Yellow Fever Vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT05374317?

This trial is sponsored by US Army Medical Research Institute of Infectious Diseases, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05374317 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.